Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks.

Sazan RasulMarcus HackerElisabeth Kretschmer-ChottAsha LeisserBernhard GrubmüllerGero KramerShahrokh ShariatWolfgang WadsakMarkus MitterhauserMarkus HartenbachAlexander R Haug

Published in: European journal of nuclear medicine and molecular imaging (2019)

Intense PSMA-RLT regime with four weekly intervals between the cycles is well-tolerated and offers favorable response rates, PFS, and survival rates for patients with mCRPC.

Keyphrases

pet ct
prostate cancer
pet imaging
squamous cell carcinoma
radical prostatectomy
small cell lung cancer
positron emission tomography
stem cells
bone marrow